Software P Pharmaceutical Executive
The Next Biopharma Revolution: Quantum Computing
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Software headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Software P Pharmaceutical Executive
The infrastructure decisions companies make today could determine how quickly they capitalize on new computational capabilities
Software B BioTechniques
Original story from the University of Utah (UT, USA). A new technology called FIRE pairs machine learning with advanced DNA sequencing to find regions of the genome that are crucial for gene regulation, providing an unprecedented look at previously mysterious parts of our DNA. Ch…
Software P Pharmafile
Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence (AI) to investigate why oestrogen receptor-positive (ER-positive) breast cancers can recur years after treatment, with the aim of identifying patients at greatest risk. Around 80% of br…
Software P pharmaphorum
4 Questions pharma leaders can’t skip before letting AI act Nicole.Raleigh Wed, 28/10/2026 - 08:00
Software S Science News
The result, one of three major claims from OpenAI, raises questions about sharing of AI-generated work
Software C Cell Systems
Sadria et al. present Deep Lineage, a deep-learning method that combines time-series single-cell RNA sequencing with clonal lineage tracing to predict early cell fate bias and reconstruct unmeasured expression states. Benchmarked against a fate-aware simulator and existing method…
Software A Arcadia Science
Transformers trained on planetary orbits can predict planet movement with high fidelity under multiple possible “world models.” Here, we apply equivalent linear mapping to precisely characterize how a transformer builds its predictions from two past planetary positions.
Software B BioPharm International
At AAPS PharmSci 360, Thermo Fisher Scientific scientists described how predictive modeling guides technology selection for poorly soluble drugs, and outlined plans to bring solvent-free KinetiSol technology to commercial scale in 2027.
Software B BioTechniques
Human brain organoids can relay signals that correspond to Braille letters – in other words, the tiny tissue cultures can now ‘read’. Making strides toward biohybrid computing, researchers from the University of Bristol (UK) have demonstrated human brain organoids capable of ‘rea…
Software P pharmaphorum
AI, start-ups, and the future of human health: AION Labs’ Mati Gill Nicole.Raleigh Tue, 27/10/2026 - 15:05
Software
MedTech Dive
Medtech CEOs and consultants advised focusing on a core market and preparing for complex processes in a highly regulated industry.
Software O Omics! Omics!
seqWell CSO Joe Mellor gave me a quick tour of their new transposase library prep product for Oxford Nanopore sequencers. Since the early days of ONT, users have had two basic choices for genome library prep: rapid method relying on transposase or the ligation kits. Rapid i…
Software W Weekly Tech+Bio
ALSO: Anthropic’s IPO and pharma, AstraZeneca’s $40M upfront for insitro's Virtual Human; 1,946 OpenAI agents read a mouse brain atlas, and more...
Software P Pharmaceutical Executive
Brox.AI’s Hamish Brocklebank on the three approaches to digital twins in pharma — and why only one-to-one clones of real individuals deliver true accuracy.
Software P Paired Ends
Anthropic’s S-1 prospectus describes ambitions for biology that go well beyond helping scientists write code and summarize papers.
Software S Science News
Superconducting cables connect quantum bits on different chips, but improvements are still needed
Software S Science News
As AI firms churn out math breakthroughs, researchers question use of Lean software as proof checker
Software O Omics! Omics!
I spent last week at ASHG in beautiful Montreal. I've scribbled many notes in my notebook, and am planning to emit a series of pieces each focused on a single topic. Some of these may be brief, but I hope still interesting. Far too many of these cover topics I h…
Software
Ground Truths
A far-ranging conversation with one of the leaders of the field
Software H Heng Li
In November 2025, the company behind the Pangram AI detector published a report claiming 21% of ICLR 2026 reviews are fully AI-generated. Shen and Wang published an independent investigation and concluded that 20% of ICLR reviews and 12% of Nature Communications reviews are mostl…
Software P Pharmaceutical Executive
Bristol Myers Squibb discloses a patient death in its Phase I CAR-T multiple sclerosis trial, Pathos AI launches multi-year collaborations with Bristol Myers Squibb and Tempus AI to advance Alzheimer’s drug development, and health economist Dr. Nadine Zawadzki speaks with The Ron…
Software S SecureBio
How capable are general purpose AI models at reproducing a published biological AI tool? Our latest benchmark helps us assess this capability on commonly used biological and chemical AI tools.
Software P Pharmaceutical Commerce
Agentic AI is moving biopharma from tools that inform decisions to systems that execute them, reshaping discovery, clinical trials, commercial launch and regulatory work.
Software
European Biotechnology
AI can already reduce administrative work, improve decision-making and streamline parts of clinical development. But its impact is often overstated. Evidenze’s Raphaela Schnurbus explains where AI is delivering measurable value today, where human expertise remains essential and…
Software P Pharmaceutical Executive
Pathos AI launches multi-year collaborations to build an AI-driven dataset for Alzheimer’s and other neurological diseases.
Software M Matt Gamber
Value creating catalysts for ****, ****, ****, ****, ****, ****, ****, ****, ****, and ****.
Software P Pharmaceutical Executive
Brox.AI’s Hamish Brocklebank on why it retired “digital twin” for “digital clone” — and why the distinction matters for pharma research accuracy.
Software
Nature Biotechnology
Software P Paired Ends
Down to a Science, UVA SDS Data Points, AI Exchange at UVA. One episode recommendation from each.
Software P Paired Ends
A limited demonstration that AI reviews can do the job of human reviewers at improving papers. Deciding what to publish still needs an accountable editor with human reviewers they trust.
Software M Mac in Chem
Burette is a macOS desktop app and Quick Look extension for molecular previews: Mol* 3D, xyzrender SVG, and RDKit grids. There is a review of
Software T The Niche
I just wrote about the complicated MUSE cell situation in the US. Marketing of these unapproved cells is all over the place now. It’s so widespread that celebrities and other well-known folks are trying MUSE cells. Trump’s granddaughter’s MUSE cell procedure For instance, now we…
Software
MedTech Dive
Provider groups are lobbying the Food and Drug Administration to make tech companies responsible for the safety and performance of generative AI-backed medical devices, arguing the tools’ makers are best equipped to evaluate them.
Software M Mac in Chem
Avogadro is an advanced open source molecular editor and visualization tool. Download and installation instructions are here https://avogadro.cc/install/index.html
Software B BioPharm International
Insilica's Dr Thomas Luechtefeld argues process traceability, not benchmark accuracy alone, determines whether AI toxicology decisions can be trusted.
Software
MedTech Dive
More than 4,000 people across the medtech sector met in Boston for one of the industry’s biggest events of the year. Catch up on all the conference news in MedTech Dive’s roundup.
Software P Pharmaceutical Commerce
AI agents are moving into healthcare faster than most organizations can supervise them. In this conversation, Amy Brown, CEO of Authenticx, argues that every AI agent will eventually fail—and that the real differentiator isn't which company deploys AI first, but which one can see…
Software P Pharmaceutical Executive
AI agents are moving into healthcare faster than most organizations can supervise them. In this conversation, Amy Brown, CEO of Authenticx, argues that every AI agent will eventually fail—and that the real differentiator isn't which company deploys AI first, but which one can see…
Software P Pharmaceutical Commerce
AI agents are moving into healthcare faster than most organizations can supervise them. In this conversation, Amy Brown, CEO of Authenticx, argues that every AI agent will eventually fail—and that the real differentiator isn't which company deploys AI first, but which one can see…